Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20128532 | 0.87 | GAA (0.31) | MCHR1GAAHTTESR2 | |
| SCHEMBL20128918 | 0.81 | ESR2 (0.36) | MCHR1GAAHTTESR2DRD2 | |
| SCHEMBL20129351 | 0.81 | MAPT (0.40) | GAADRD2 | |
| SCHEMBL20126199 | 0.81 | TLR9 (0.33) | GPR119MCHR1HCRTR2GAAESR2 | |
| SCHEMBL20126323 | 0.81 | DRD2 (0.35) | GPR119MCHR1HCRTR2ESR2DRD2 | |
| SCHEMBL20126223 | 0.78 | — | — | |
| SCHEMBL20126322 | 0.77 | MCHR1 (0.38) | GPR119MCHR1DRD2 | |
| SCHEMBL20128878 | 0.76 | CYP2C9 (0.54) | ESR2DRD2 | |
| SCHEMBL20126174 | 0.74 | DRD2 (0.40) | MCHR1DRD2 | |
| SCHEMBL20129423 | 0.73 | CYP2C9 (0.44) | GAAESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | DRD1, PLD1, DRD2 | GPR119 3774/4885MCHR1 1562/4885HCRTR2 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.